Last reviewed · How we verify
TT-034
At a glance
| Generic name | TT-034 |
|---|---|
| Sponsor | Tacere Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.
- Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TT-034 CI brief — competitive landscape report
- TT-034 updates RSS · CI watch RSS
- Tacere Therapeutics, Inc. portfolio CI